Last reviewed · How we verify
Active bupivacaine 0.375% PENG block
Bupivacaine blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce local anesthesia.
Bupivacaine blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce local anesthesia. Used for Local and regional anesthesia via PENG block for lower limb surgical procedures and pain management.
At a glance
| Generic name | Active bupivacaine 0.375% PENG block |
|---|---|
| Also known as | Active Pericapsular Nerve Group block |
| Sponsor | University of California, San Diego |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Bupivacaine is a long-acting amide local anesthetic that reversibly inhibits sodium influx through voltage-gated sodium channels in nerve cell membranes. This prevents depolarization and conduction of nerve impulses, resulting in local anesthesia. The PENG (Pectineus Fascia Iliopsoas Nerve Groove) block is a regional anesthesia technique that delivers bupivacaine to block the femoral and obturator nerves for lower limb anesthesia.
Approved indications
- Local and regional anesthesia via PENG block for lower limb surgical procedures and pain management
Common side effects
- Systemic toxicity (CNS effects: tremor, seizures)
- Cardiovascular effects (hypotension, arrhythmias)
- Local tissue irritation or nerve injury
- Allergic reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: